6 completed. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 6 |
| Phase 1 | 1 | Completed 1 |
Follow Pituitary ACTH Hypersecretion: new trials by email Literature Review of Pituitary ACTH Hypersecretion trials Research Report on Pituitary ACTH Hypersecretion
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome atumelnant - Cushing Syndrome, Cushing Disease | Phase 1 / Phase 2 | Completed | Crinetics Pharmaceuticals Inc. | 19 | 2023-10-12 | 2026-10-14 |
| SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome SPI-62, Placebo - Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion | Phase 2 | Completed | Sparrow Pharmaceuticals | 26 | 2022-09-01 | 2025-10-08 |
| Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease Seliciclib - Cushing Disease | Phase 2 | Completed | Cedars-Sinai Medical Center | 5 | 2018-11-02 | 2026-10-16 |
| Study to Evaluate CORT125134 in Participants With Cushing's Syndrome CORT125134 - Cushing's Syndrome | Phase 2 | Completed | Corcept Therapeutics | 35 | 2016-06-01 | 2019-10-15 |
| Safety and Efficacy of LCI699 in Cushing's Disease Patients LCI699 - Cushings Disease, Cushing Disease | Phase 2 | Completed | Novartis Pharmaceuticals | 31 | 2011-03-23 | 2021-01-22 |
| Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease Pasireotide - Cushing Disease | Phase 2 | Completed | Novartis Pharmaceuticals | 19 | 2004-08-13 | 2021-06-02 |
ACTH Syndrome, Ectopic (3) · Cushing Syndrome (3) · Adrenal Cortex Neoplasms (1) · Adrenocortical Carcinoma (1) · Adrenocortical Hyperfunction (1) · Diabetes Mellitus, Type 2 (1) · Hypertension (1) · Pituitary Diseases (1)
Brain Diseases (6) · Central Nervous System Diseases (6) · Endocrine System Diseases (6) · Hyperpituitarism (6) · Hypothalamic Diseases (6) · Nervous System Diseases (6) · Pituitary Diseases (5) · Adrenal Gland Diseases (4) · Adrenocortical Hyperfunction (3) · Neoplasms (3) · Paraneoplastic Endocrine Syndromes (3) · Paraneoplastic Syndromes (3) · Adenocarcinoma (1) · Adrenal Cortex Diseases (1) · Adrenal Gland Neoplasms (1)
Osilodrostat (1) · Roscovitine (1) · pasireotide (1) · relacorilant (1)
Novartis Pharmaceuticals (2) · Cedars-Sinai Medical Center (1) · Corcept Therapeutics (1) · Crinetics Pharmaceuticals Inc. (1) · Sparrow Pharmaceuticals (1)
United States (6) · Italy (3) · France (2) · United Kingdom (2) · Bulgaria (1) · Germany (1) · Hungary (1) · Japan (1) · Netherlands (1) · Romania (1)
Andreas G Moraitis, MD (1) · Frank Czerwiec, MD (1) · Ning-Ai Liu, MD, PhD (1) · Shlomo Melmed, MD (1)
PMID 23943009, PMID 24423285, PMID 34335465, PMID 35058882, PMID 41052284
2004 (1)